Table 3: Mean scores for efficacy parameters at each week.

Statistics Baseline  (n=394) Week 1 (n=394) Week 4    (n=394) Week 12 (n=394) Week 26 (n=394) Week 39 (n=388) Week 52 (n=388)
Improvement of WOMAC A1 Sub-Score from Baseline
   Mean±SD -11.8±16.5 -18.5±18.4 -25.1±19.1 -28.0±19.9 -30.1±21.4 -32.7±20.0
   p value* <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Change of WOMAC A Score from Baseline
   Mean±SD -10.2±13.9 -17.6±16.2 -23.1±17.7 -25.7±18.6 -26.3±20.1 -29.2±19.2
   p value* <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Change of WOMAC B Score from Baseline
   Mean±SD -9.61±16.4 -15.3±19.4 -20.9±21.9 -22.9±22.0 -23.6±22.9 -25.7±22.0
   p value* <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Change of WOMAC C Score from Baseline
   Mean±SD -9.5±13.1 -15.7±15.8 -20.9±18.5 -22.6±19.8 -23.3±20.5 -25.7±19.5
   p value* <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Proportion of Patients in Each PTGA Score Rating, n (%)
   Very well 5 (1.3) 9 (2.3) 22 (5.6) 37 (9.4) 54 (13.7) 70 (18.0) 82 (21.1)
   Well 54 (13.7) 94 (23.9) 126 (32.0) 165 (41.9) 179 (45.4) 178 (45.9) 175 (45.1)
   Fair 124 (31.5) 199 (50.5) 202 (51.3) 165 (41.9) 127 (32.2) 118 (30.4) 90 (23.2)
   Poor 183 (46.4) 89 (22.6) 40 (10.2) 26 (6.6) 32 (8.1) 21 (5.4) 40 (10.3)
   Very poor 25 (6.3) 3 (0.8) 4 (1.0) 1 (0.3) 2 (0.5) 1 (0.3) 1 (0.3)
   Missing 3 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
   p value ** <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Proportion of Patients in Each COGA Score Rating, n (%)
   Very well 9 (2.3) 15 (3.8) 28 (7.1) 38 (9.6) 56 (14.2) 68 (17.5) 77 (19.8)
   Well 55 (14.0) 102 (25.9) 142 (36.0) 181 (45.9) 181 (45.9) 179 (46.1) 177 (45.6)
   Fair 153 (38.8) 190 (48.2) 190 (48.2) 150 (38.1) 129 (32.7) 119 (30.7) 98 (25.3)
   Poor 172 (43.7) 84 (21.3) 33 (8.4) 24 (6.1) 27 (6.9) 21 (5.4) 35 (9.0)
   Very poor 5 (1.3) 3 (0.8) 1 (0.3) 1 (0.3) 1 (0.3) 1 (0.3) 1 (0.3)
   p value ** <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Statistics   Week 1 (n=390) Week 4  (n=390) Week 12 (n=378) Week 26 (n=372) Week 39 (n=362) Week 52 (n=369)
Proportion of Patients in Each Group of Concomitant OA Treatment and Medication, n (%)
   Increased therapy 24 (6.2) 12 (3.1) 16 (4.2) 10 (2.7) 7 (1.9) 5 (1.4)
   Decreased therapy 59 (15.1) 57 (14.6) 33 (8.7) 33 (8.9) 3 (0.8) 2 (0.5)
   No change in therapy 307 (78.7) 321 (82.3) 329 (87.0) 329 (88.4) 352 (97.2) 36362 (98.1)

* p value was calculated using paired t-test.
* p value was calculated using McNemar-Bowkers test.
Last Observation Carried Forward methodology was used. At Week 26, six patients received repeat treatment, which with LOCF, allowed data for 388 patients.

Back to Article